文献速递瓣膜外科

RESILIA组织瓣在二叶式主动脉瓣置换患者中的七年结果:年龄与瓣膜尺寸考量

Seven-Year Results for RESILIA Tissue in Bicuspid Aortic Valve Replacement Patients: Age and Valve Size Considerations.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-01-01

COMMENCE单臂非随机多中心研究比较了二叶式与三叶式主动脉瓣患者使用RESILIA组织瓣7年结局,二叶式患者更年轻(平均59.8岁 vs 70.2岁,P<.001)。7年随访二叶式患者无结构性瓣膜 deterioration 证据,倾向评分和年龄调整后生存率(91.9% vs 88.1%,P=.35)、卒中及再手术无显著差异。

要点

  • 二叶式主动脉瓣患者使用RESILIA组织瓣7年无结构性瓣膜 deterioration 证据。
  • 倾向评分和年龄调整后二叶式与三叶式患者7年生存率无显著差异。
  • 65岁以下二叶式患者术后3个月与7年有效开口面积和平均压差无显著差异。

核心结论

  • 二叶式主动脉瓣患者使用RESILIA组织瓣7年结局优异,无结构性瓣膜 deterioration 证据,为希望避免抗凝的精选年轻患者提供持久选择。

研究设计与样本

  • COMMENCE试验为多中心单臂非随机研究,纳入672例原生主动脉瓣置换患者,其中二叶式214例、三叶式458例,采用倾向评分逆概率治疗加权分析。

主要发现

  • 二叶式患者平均年龄59.8(12.4)岁,显著低于三叶式的70.2(9.5)岁(P<.001),其中39/214(18%)二叶式患者<50岁。
  • 7年随访二叶式患者无结构性瓣膜 deterioration 证据。
  • 7年时二叶式与三叶式患者倾向评分和年龄调整后生存率分别为91.9% vs 88.1%(P=.35),卒中及再手术无显著差异。
  • 65岁以下二叶式患者术后3个月与7年假体瓣有效开口面积和平均压差无显著差异。

临床怎么用

  • 对于需行主动脉瓣置换、希望避免终身抗凝的精选年轻二叶式主动脉瓣患者,RESILIA组织瓣可考虑作为持久选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with bicuspid aortic valve disease requiring surgical aortic valve replacement are often younger and want to avoid lifelong anticoagulation. A multicentre single-arm non-randomized study, the COMMENCE trial, studied outcomes of RESILIA tissue aortic valves in bicuspid aortic valve patients through 7 years of follow-up. METHODS: Of 672 patients who underwent surgical replacement of native aortic valves, 214 had bicuspid and 458 had tricuspid aortic valves. Propensity score analyses with inverse probability of treatment weighting were utilized to minimize bias due to measured confounders. Linear mixed-effect models compared longitudinal changes in haemodynamic parameters. RESULTS: Patients with bicuspid were significantly younger than those with tricuspid aortic valves-mean age of bicuspid: 59.8 (12.4) vs tricuspid: 70.2 (9.5) years; P < .001; 39/214 (18%) bicuspid aortic valve patients were <50 years old. There was no evidence of structural valve deterioration in any bicuspid aortic valve patients over 7 years of follow-up. At 7 years, there was no significant difference between bicuspid and tricuspid aortic valve patients in propensity score- and age-adjusted survival (91.9% vs 88.1%, respectively; P = .35), stroke, or reoperation. Among bicuspid aortic valve patients <65 years of age, there was no significant difference in prosthetic valve effective orifice areas and mean gradients between 3 months and 7 years postoperatively. CONCLUSIONS: Patients with bicuspid aortic valves had excellent outcomes with RESILIA tissue valves at 7 years with no evidence of structural valve deterioration. These results suggest a durable alternative for carefully selected younger patients wishing to avoid anticoagulation. CLINICAL TRIAL REGISTRATION NUMBER: NCT01757665.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Salna M, Bavaria JE, Heimansohn D, et al. Seven-Year Results for RESILIA Tissue in Bicuspid Aortic Valve Replacement Patients: Age and Valve Size Considerations. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40748697. doi:10.1093/icvts/ivaf176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。